CleanCore Solutions, Inc. (ZONE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value 329.39%; Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 329.39% | Share-based compensation / revenue. Period ending 2026-03-31. $11.24M ÷ $3.41M × 100 ≈ 329.39% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 3.41M USD | |
| Stock-based compensation | 11.24M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -51.80M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $3.41M | $11.24M | $-45.01M | (m) | (m) | 329.39% | (m) | (m) |
| 2025-12-31 | (m) | $3.42M | $10.71M | $-33.54M | (m) | (m) | 312.85% | (m) | (m) |
| 2025-09-30 | (m) | $2.61M | $4.19M | $-13.81M | (m) | (m) | 160.32% | (m) | (m) |
| 2025-06-30 | (m) | $2.07M | $3.20M | $-6.39M | (m) | (m) | 154.53% | (m) | (m) |
| 2025-03-31 | (m) | $1.89M | $1.08M | $-3.37M | (m) | (m) | 57.27% | (m) | (m) |
| 2024-12-31 | (m) | $1.64M | $894.79K | $-3.09M | (m) | (m) | 54.46% | (m) | (m) |
| 2024-09-30 | (m) | $1.64M | $789.40K | $-2.39M | (m) | (m) | 48.01% | (m) | (m) |
| 2024-06-30 | (m) | $1.60M | $670.96K | $-1.95M | (m) | (m) | 41.80% | (m) | (m) |
| 2024-03-31 | (m) | $1.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-10-16 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CLOROX CO /DE/ (CLX) | United States | $9.895B | 16.58 |